We have developed a blood spot assay for thyroid stimulating hormone (TSH) based on the Amerlite TSH-30 serum assay for use in the Welsh neonatal hypothyroid screening programme. A total of 67656 infants were screened in 1994 and 1995, and 28 cases of primary hypothyroidism were detected, giving a prevalence of one in 2416. The method is sensitive and rapid, results being available within 3 h of receipt of samples. The assay enables much faster detection of primary hypothyroidism than was previously possible, and therefore contributes to earlier treatment of affected infants.
Screening programmes for the diagnosis of congenital hypothyroidism have been in place for 20 years in some countries. Diagnosis is commonly made by detection of thyroid stimulating hormone (TSH) in blood spot samples on filter paper collected in the first week of life. This strategy enables the detection of cases of primary hypothyroidism in which TSH concentrations are invariably raised, but will not detect infants with the rarer disorder of secondary hypothyroidism.' A congenital hypothyroidism screening programme was set up in Wales in January 1981 using a two-site immunoradiometric assay (IRMA) automated on a Kemtek 4400 immunoassay analyser? Newer TSH assays have been introduced utilizing non-isotopic labels such as fluorometric or enzyme linked chemiluminescent end points, which offer advantages of better sensitivity and greater convenience. In this paper, we report the development of a method for the measurement of TSH in neonatal blood spot samples based upon the Amerlite TSH-30 assay, and the results obtained from routine screening of samples over a 2 year period. The impact on the Welsh screening programme for congenital hypothyroidism is assessed.
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MATERIALS AND METHODS
Reagents
The Amerlite TSH-30 kit (designed for measurement of serum samples), Amerlite wash buffer and Amerlite signal reagent were obtained from Ortho Clinical Diagnostics (Amersham, UK). TSH-30 coated microtitre wells and conjugate reagent were used according to the manufacturer's instructions. Elution buffer was 5 mM phosphate buffered saline (0,9% w/v) containing bovine serum albumin (0'5% w/v) and sodium azide (0,2% w/v), pH 7·8 and was stored at 4°C. Blood spot TSH standards were prepared as previously described.? and covered the assay range 0-185 ml.I/L. 125I-labelled TSH was obtained from Ortho Clinical Diagnostics and filter paper from Schleicher & Schuell [type 2992 (Anderman Co Ltd, Surrey, UK)] was used for preparation of standards, quality control and sample blood spots. Standards and quality control samples were stored in sealed polythene bags at -20°C.
Assay protocol Delivery of 4 mm diameter standard and sample spots directly into anti-TSH monoclonal antibody coated wells was carried out using an automatic punching device. This was by means of a Wallac DELFIA plate punch which had been modified by Ortho Clinical Diagnostics to punch 4 mm diameter blood spot samples instead of the usual 3 mm samples. One hundred microlitres of elution buffer was added and the wells incubated for I h at room temperature using the Amerlite shaker incubator. After incubation, the filter paper spots were removed using a vacuum line and the wells washed using the Amerlite washer. One hundred microlitres of horseradish peroxidase labelled anti-fJ subunit of TSH monoclonal antibody was added and the wells incubated for I h at 37°C using the Amerlite shaker incubator. The wells were washed before addition of 250 ilL of signal reagent. The light emitted from the chemiluminescent reaction was measured after 10min at room temperature using the Amerlite luminometer.
Assessment of accuracy
To assess the accuracy of the assay, 19 serum samples with increased TSH concentrations of between 18 and 130mUjL (determined from the Amerlite TSH-30 serum assay) were mixed with an equal quantity of washed red blood cells. Twenty-five micro litre samples were spotted onto the same Schleicher & Schuell type 2992 filter paper cards as used for collecting infant samples; and assayed after drying using the protocol described. Results from the neonatal TSH assay were multiplied by two to account for the dilution with erythrocytes.
Patient samples
Patient specimens were routine heel prick blood samples collected on to neonatal screening cards 6 days after birth. Each sample was visually inspected before use to ensure that a 4mm blood spot could be punched to give a completely saturated blood spot. Repeat blood spots were requested if the sample did not meet this criterion. Samples were tested in singleton. In the Welsh screening programme TSH results less than 10mU jL are regarded as normal. Results greater than lOmUjL are confirmed by testing a second spot punched from the same card. If an increased blood spot TSH concentration is confirmed the following protocol is followed. For results between 10 and 20mUjL, a second blood spot card is collected from the infant, and above 20mUjL the infant is seen by a paediatrician for a complete clinical and biochemical evaluation.
Quality control QC blood spots at two TSH concentrations were run in singleton at the beginning of each assay run. Samples from the UK National External
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Quality Assurance Scheme (UKNEQAS) were run throughout 1994 and 1995.
RESULTS
Assay optimization
The effect of length of incubation of blood spots with elution buffer and conjugate incubation time was studied. The dose response plots generated showed no significant differences with times varying between 30 and 120 min for either elution or conjugate incubation although the absolute light units produced were decreased with shorter incubation periods. Studies using spots of blood samples prepared with radioiodinated TSH demonstrated that >95% of TSH was eluted from the paper after 60 min incubation with elution buffer, and this time was selected for further work. Sixty minutes incubation period with conjugate reagent was also chosen.
Accuracy
A comparison of blood spot results (measured in the neonatal TSH method) with serum assay values (obtained in the Amerlite TSH-30 kit), gave good agreement (y= 1·17x-6·6, r=0'98, where y is the blood spot TSH concentration multiplied by two and x is the serum TSH concentration). This indicates that accurate TSH results are obtained with this modification of the kit using a blood spot standard calibration. The overall UKNEQAS data for 1995 showed a cumulative bias of -8,5% and cumulative variability of 18·3% calculated against the all laboratory mean. Performance is considered unacceptable in this scheme if bias exceeds ±25% and variability exceeds 30%.
Sensitivity and precision
The analytical sensitivity of the method was determined by assaying 25 replicates of a TSHfree blood spot and reading the mean [2 standard deviation (SD)] light units from the standard curve. A detection limit of 1·2 mU jL was found. Within and between run precision was determined using two blood spot pools. Each pool was tested 12 times to give within assay results, and in 24 assays for between assay data. At mean blood spot TSH concentrations of 12 and 50mUjL the within run precision gave a coefficient of variation (CV) of 14·3% and 9,3%, and at mean blood spot TSH concentrations of nine and 34mUjL the between run precision gave a CV of 12·3% and 9·9%. 
Infants with blood spot thyroid stimulating hormone (TSH) between 20 and 50mUIL and increased serum TSH concentrations by Amerlite assay
have permanent primary hypothyroidism. To date no false negatives have been reported to us over the last 2 years since introducing the Amerlite assay. The prevalence of primary hypothyroidism detected in infants in 1994 and 1995 combined was one in 2416. The performance requirements of an assay method to be used for screening large numbers of patient samples dictate that the method should be rapid, reliable and ideally automated. For congenital hypothyroid screening using TSH measurement good sensitivity is also important. A sensitive method enables the selection of a low cut-off value to prevent false negative results, whilst keeping the repeat testing due to false positive results appropriately low. The detection limit of the neonatal TSH method described was
Clinical results
During 1994 and 1995, a total of 67656 blood spots from infants born in Wales were screened using the Amerlite method. The distribution of TSH results is shown in Table 1 , and is compared with results from the previous 2 years 1992 and 1993 obtained using the two-site immunoradiometric assay. With the Amerlite method, 99·9% of samples gave TSH results < lOmUjL which is comparable to the previous two years' data. Sixty-three samples gave results > IOmUjL, of which 28 were from infants with primary hypothyroidism and 35 were false positive results, giving a false positive rate of 0·05% overall. Of the 35 with false positive results, 24 had blood spot TSH concentrations between 10 and 20mUjL but were less than IOmUjL on repeat assay from a second neonatal screening card. The remaining 11 with blood spot TSH concentrations between 20 and 50mU jL, on repeat assay with either a second neonatal screening card or a serum sample gave normal TSH concentrations. There were six samples, as shown in Table 2 , with TSH concentrations between 20 and 50mUjL which on recall of infants all had serum TSH concentrations between 23 and 162mUjL with low FT 4 concentrations. Twenty-two infants with blood spot TSH concentrations greater than 50 mUjL, on recall had serum TSH concentrations, between 83 and 1190mUjL with low FT 4 concentrations. Twenty-eight infants were presumed to have primary hypothyroidism and were started on T4 replacement. They will be reviewed at 2 years of age by stopping their thyroxine replacement to assess whether all 28 found to be 1'2mUjL, which is adequate for screening purposes, and far superior to the sensitivity obtained from the previously used IRMA method. Within-and between-run precision was acceptable for a screening assay. I The Amerlite TSH-30 assay method described for neonatal blood spot samples can be completed within 3 h of sample receipt. The fast turnaround time means that samples with increased TSH concentrations can be confirmed with a repeat assay on the same day, rather than on the following day as was previously done using the IRMA method, so allowing confirmation of diagnosis to be made earlier. We now run neonatal TSH assays daily instead of four times a week.
The new method has proved to be reliable from screening results obtained over 2 years. Thirty-five false positive results were obtained, but more importantly no hypothyroid infants were missed as a consequence of false negative results. The number of false positive results would be reduced by one-half if a 15mUjL cutoff value was used instead of lOmUjL. If this cut-off had been employed throughout 1994 and 1995, no hypothyroid infants would have been missed and the recall rate due to false positives would have been 0·026%. Twenty-eight infants with congenital hypothyroidism were successfully identified from a newborn population of 67656,
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yielding a prevalence for the disorder of 1:2416. This prevalence is consistent with published epidemiological data on congenital hypothyroidism throughout Europe.'
In conclusion, we have developed a chemiluminescent method for measurement of TSH in blood spot samples based on the Amerlite TSH-30 kit. Two years' experience with the new assay for screening of neonatal TSH samples in Wales has demonstrated that the method is clinically reliable.
